Amicus Therapeutics (NASDAQ:FOLD) has announced a resolution to its patent litigation case with Teva Pharmaceuticals (NYSE:TEVA) through a new license agreement.
The dispute arose following Teva’s submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the drug Galafold® (migalastat) 123 mg oral capsules, which was contested by Amicus due to patent infringement concerns.
Under the terms of the agreement, Teva will be granted a non-exclusive license to commercialize its generic Galafold in the United States starting in January 2037 or earlier.
In exchange, Amicus will drop its pending litigation against Teva.
While the settlement with Teva is complete, Amicus's patent disputes with Aurobindo Pharma and Lupin Pharmaceuticals will continue.